FDA and Novo Nordisk Alert Consumers to Counterfeit Ozempic
By Stephanie Brown HealthDay Reporter
MONDAY, April 21, 2025 -- The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout for counterfeit Ozempic (semaglutide) and to refrain from using the imitation drugs.
Several hundred units of Ozempic injection 1 mg have found their way into the drug supply chain in the United States. The seized counterfeit products display a combination of lot number PAR0362 (an authentic lot number) and illegitimate serial numbers that begin with the following eight digits: 51746517. Only products with this lot number coupled with the erroneous serial number are considered counterfeit products.
The FDA and Novo Nordisk are currently testing the seized products but do not yet have any information regarding the identity, quality, or safety of these drugs. The FDA investigation is ongoing.
Six adverse event reports have been received by the FDA related to this particular lot of Ozempic. However, these reports, all submitted by Novo Nordisk, do not appear to be connected to the counterfeit product.
Pharmacies and patients are urged to double-check their Ozempic box to see if it features the combination of lot number and incorrect serial number. If so, these products are considered counterfeit and should not be used.
Suspicious Ozempic products should be reported to Novo Nordisk or directly to the FDA. In addition, any adverse effects from the use of Ozempic should be reported to the FDA MedWatch Safety Information and Adverse Event Reporting Program and to Novo Nordisk (1-800-727-6500).
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
GLP-1 Drugs Appear To Lower Cancer Risk
MONDAY, May 19, 2025 — Cutting-edge GLP-1 weight-loss drugs appear to help lower cancer risk even beyond the benefits from dropping excess pounds, a new study...
Novo Nordisk, U.S. Biotech Company Team Up to Create Obesity Pills
FRIDAY, May 16, 2025 — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other...
More U.S. Teens Getting Weight-Loss Surgery
WEDNESDAY, May 14, 2025 — More U.S. teenagers are getting weight-loss surgery, despite the discovery of new drugs like Ozempic/Wegovy that help people drop pounds...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.